{"id":"isoniazid-aminosalicylate-tablets","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Gastrointestinal disturbance (nausea, vomiting, diarrhea)"},{"rate":"5-15","effect":"Peripheral neuropathy"},{"rate":"1-5","effect":"Hepatotoxicity"},{"rate":"1-3","effect":"Hypersensitivity reactions"},{"rate":"5-10","effect":"Arthralgias"}]},"_chembl":{"chemblId":"CHEMBL64","moleculeType":"Small molecule","molecularWeight":"137.14"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isoniazid is a prodrug that inhibits mycolic acid synthesis in the mycobacterial cell wall after activation by catalase-peroxidase. Aminosalicylate (para-aminosalicylic acid) inhibits folate synthesis and acts as a second-line agent. Together in a fixed-dose combination, they provide complementary bactericidal and bacteriostatic activity against tuberculosis.","oneSentence":"Isoniazid and aminosalicylate work synergistically to inhibit mycobacterial cell wall synthesis and folate metabolism, killing Mycobacterium tuberculosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:50:18.878Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"},{"name":"Drug-resistant tuberculosis (as part of combination therapy)"}]},"trialDetails":[{"nctId":"NCT02331823","phase":"PHASE4","title":"Research on New Regimens for Retreatment Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2013-06","conditions":"Reinfection Pulmonary Tuberculosis","enrollment":864}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ethambutol tablets","pyrazinamide tablets","rifabutin capsules","moxifloxacin tablets"],"phase":"marketed","status":"active","brandName":"Isoniazid Aminosalicylate Tablets","genericName":"Isoniazid Aminosalicylate Tablets","companyName":"Shanghai Pulmonary Hospital, Shanghai, China","companyId":"shanghai-pulmonary-hospital-shanghai-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isoniazid and aminosalicylate work synergistically to inhibit mycobacterial cell wall synthesis and folate metabolism, killing Mycobacterium tuberculosis. Used for Tuberculosis (pulmonary and extrapulmonary), Drug-resistant tuberculosis (as part of combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}